Therapeutic options in relapsed or refractory peripheral T-cell lymphoma

Cancer Treatment Reviews

Volumn 40, Issue 9, 2014, Pages 1080-1088

  Coiffier, Bertrand ^a   Federico, Massimo ^b   Caballero, Dolores ^c   Dearden, Claire ^d   Morschhauser, Franck ^e   Jäger, Ulrich ^f   Trümper, Lorenz ^g   Zucca, Emanuele ^h   Gomes da Silva, Maria ⁱ   Pettengell, Ruth ^j   Weidmann, Eckhart ^k   d'Amore, Francesco ^l   Tilly, Hervé ^m   Zinzani, Pier Luigi ⁿ  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA IBSAL   (Spain)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g UNIVERSITY OF GÖTTINGEN   (Germany)

^h OSPEDALE SAN GIOVANNI   (Switzerland)

ⁱ INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^j ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^k KRANKENHAUS NORDWEST   (Germany)

^l AARHUS UNIVERSITY HOSPITAL   (Denmark)

^m UNIVERSITÉ DE ROUEN   (France)

ⁿ UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

Antifolate; Fusion protein; Histone deacetylase inhibitor; Immunomodulatory agent; Nucleoside analog; Peripheral T cell lymphoma

Indexed keywords

ALEMTUZUMAB; ALISERTIB; ALPHA INTERFERON; ASPARAGINASE; BELINOSTAT; BENDAMUSTINE; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEHYDRODIDEMNIN B; DENILEUKIN DIFTITOX; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; ISOTRETINOIN; LENALIDOMIDE; METHOTREXATE; MOGAMULIZUMAB; PENTOSTATIN; PRALATREXATE; PREDNISONE; ROMIDEPSIN; TIPIFARNIB; UNINDEXED DRUG; VINCRISTINE SULFATE; ZANOLIMUMAB; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CAC10-VCMMAE; DEPSIPEPTIDE; DIPHTHERIA TOXIN; DNA TOPOISOMERASE INHIBITOR; FOLIC ACID ANTAGONIST; HISTONE DEACETYLASE INHIBITOR; HYBRID PROTEIN; INTERLEUKIN 2; MONOCLONAL ANTIBODY; PREDNISOLONE; THALIDOMIDE; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; HUMAN; MONOTHERAPY; PERIPHERAL T CELL LYMPHOMA; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; ANALOGS AND DERIVATIVES; LYMPHOMA, T-CELL, PERIPHERAL; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; STEM CELL TRANSPLANTATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEPSIPEPTIDES; DIPHTHERIA TOXIN; DOXORUBICIN; FOLIC ACID ANTAGONISTS; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOCONJUGATES; INTERLEUKIN-2; LYMPHOMA, T-CELL, PERIPHERAL; NEOPLASM RECURRENCE, LOCAL; PREDNISOLONE; RECOMBINANT FUSION PROTEINS; STEM CELL TRANSPLANTATION; THALIDOMIDE; TOPOISOMERASE INHIBITORS; VINCRISTINE;

EID: 84928763763     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.08.001     Document Type: Review

References (91)

1. Swerdlow S.H., Campo E., Harris N.L., et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, World Health Organization, Lyon. 4th ed.
2. Vose J., Armitage J., Weisenburger D. International T-cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008, 26:4124-4130.
3. Foss F. Hematology: relapsed and refractory PTCL-into the therapeutic abyss. Nat Rev Clin Oncol 2011, 8:321-322.
4. Schmitz N., Trümper L., Ziepert M., et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010, 116:3418-3425.
5. Abouyabis A.N., Shenoy P.J., Sinha R., Flowers C.R., Lechowicz M.J. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol 2011, 2011:623924.
6. Weisenburger D.D., Savage K.J., Harris N.L., et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011, 117:3402-3408.
7. Gisselbrecht C., Gaulard P., Lepage E., et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998, 92:76-82.
8. Corradini P., Tarella C., Zallio F., et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006, 20:1533-1538.
9. Rodríguez J., Conde E., Gutiérrez A., et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007, 79:32-38.
10. Mercadal S., Briones J., Xicoy B., et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008, 19:958-963.
11. Enblad G., Hagberg H., Erlanson M., et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004, 103:2920-2924.
12. Zinzani P.L., Alinari L., Tani M., Fina M., Pileri S., Baccarani M. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica 2005, 90:702-703.
13. Friedberg J.W., Mahadevan D., Cebula E., et al. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol 2014, 32:44-50.
14. O'Connor O.A., Masszi T., Savage K.J., et al. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): results from the BELIEF trial. J Clin Oncol 2013, 31(Suppl). [abstract 8507].
15. Damaj G., Gressin R., Bouabdallah K., et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol 2013, 31:104-110.
16. Zinzani P.L., Musuraca G., Tani M., et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007, 25:4293-4297.
17. Pro B., Advani R., Brice P., et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: results of a phase II study. J Clin Oncol 2012, 30:2190-2196.
18. Horwitz S.M., Advani R.H., Bartlett N.L., et al. Objective responses in relapsed T-cell lymphomas with single agent brentuximab vedotin. Blood 2014, 123:3095-3100.
19. Dang N.H., Pro B., Hagemeister F.B., et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 2007, 136:439-447.
20. Zinzani P.L., Magagnoli M., Bendandi M., et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 1998, 9:1351-1353.
21. Sallah S., Wan J.Y., Nguyen N.P. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 2001, 113:185-187.
22. Zinzani P.L., Venturini F., Stefoni V., et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 2010, 21:860-863.
23. Dueck G., Chua N., Prasad A., et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 2010, 116:4541-4548.
24. Zinzani P.L., Pellegrini C., Broccoli A., et al. Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. Leuk Lymphoma 2011, 52:1585-1588.
25. Ishida T., Joh T., Uike N., et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012, 30:837-842.
26. Ogura M., Ishida T., Hatake K., et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CC chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol 2014, 32:1157-1163.
27. Monfardini S., Sorio R., Cavalli F., et al. Pentostatin (2'-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: phase II study of the EORTC Early Clinical Trials Group. Oncology 1996, 53:163-168.
28. Tsimberidou A.M., Giles F., Duvic M., Fayad L., Kurzrock R. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. Cancer 2004, 100:342-349.
29. Dang N.H., Hagemeister F.B., Duvic M., et al. Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. Oncol Rep 2003, 10:1513-1518.
30. Ribrag V., Caballero D., Fermé C., et al. Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma. Haematologica 2013, 98:357-363.
31. O'Connor O.A., Horwitz S., Hamlin P., et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 2009, 27:4357-4364.
32. O'Connor O.A., Pro B., Pinter-Brown L., et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011, 29:1182-1189.
33. Piekarz R.L., Frye R., Prince H.M., et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011, 117:5827-5834.
34. Coiffier B., Pro B., Prince H.M., et al. Results from a pivotal, open label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012, 30:631-636.
35. Coiffier B., Pro B., Prince H.M., et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol 2014, 7:11.
36. Witzig T.E., Tang H., Micallef I.N., et al. Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood 2011, 118:4882-4889.
37. d'Amore F., Radford J., Relander T., et al. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. Br J Haematol 2010, 150:565-573.
38. Younes A., Bartlett N.L., Leonard J.P., et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010, 363:1812-1821.
39. Ansell S.M., Horwitz S.M., Engert A., et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007, 25:2764-2769.
40. Bartlett N.L., Younes A., Carabasi M.H., et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2008, 111:1848-1854.
41. Forero-Torres A., Leonard J.P., Younes A., et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009, 146:171-179.
42. Francisco J.A., Cerveny C.G., Meyer D.L., et al. CAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003, 102:1458-1465.
43. d'Amore F., Leppä S., Gomes da Silva M., et al. First interim efficacy and safety analysis of an international phase III randomized trial in newly diagnosed systemic peripheral T-cell lymphoma treated with chemotherapy with or without alemtuzumab and consolidated by high dose therapy. Blood 2012, 120. [abstract 57].
44. Morschhauser F., Fitoussi O., Haioun C., et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer 2013, 49:2869-2876.
45. Sandor V., Senderowicz A., Mertins S., et al. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 2000, 83:817-825.
46. Marks P.A., Richon V.M., Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000, 92:1210-1216.
47. Bates S.E., Zhan Z., Steadman K., et al. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol 2010, 148:256-267.
48. Konsoula Z., Velena A., Lee R., Dritschilo A., Jung M. Histone deacetylase inhibitor: antineoplastic agent and radiation modulator. Adv Exp Med Biol 2011, 720:171-179.
49. Luchenko V.L., Salcido C.D., Zhang Y., et al. Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer. Cell Cycle 2011, 10:3119-3128.
50. Ueda H., Nakajima H., Hori Y., et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 1994, 47:301-310.
51. Nakajima H., Kim Y.B., Terano H., Yoshida M., Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 1998, 241:126-133.
52. Khan N., Jeffers M., Kumar S., et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008, 409:581-589.
53. Gonen N., Assaraf Y.G. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat 2012, 15:183-210.
54. Weidle U.H., Schneider B., Georges G., Brinkmann U. Genetically engineered fusion proteins for treatment of cancer. Cancer Genomics Proteomics 2012, 9:357-372.
55. Foss F.M., Sjak-Shie N., Goy A., et al. A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. Leuk Lymphoma 2013, 54:1373-1379.
56. Robak T., Lech-Maranda E., Korycka A., Robak E. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Curr Med Chem 2006, 13:3165-3189.
57. Mercieca J., Matutes E., Dearden C., MacLennan K., Catorsky D. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 1994, 12:2588-2593.
58. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphomas. Version 3. Available from: ; 2012. http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf.
59. Velasquez W.S., Cabanillas F., Salvador P., et al. Effective salvage therapy for lymphoma with cisplatin in combination with high dose Ara-C and dexamethasone (DHAP). Blood 1988, 71:117-122.
60. Velasquez W.S., McLaughlin P., Tucker S., et al. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994, 12:1169-1176.
61. Zelenetz A.D., Hamlin P., Kewalramani T., Yahalom J., Nimer S., Moskowitz C.H. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2003, 14(Suppl. 1):i5-i10.
62. Emmanouilides C., Colovos C., Pinter-Brown L., et al. Pilot study of fixed-infusion rate gemcitabine with cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. Clin Lymphoma 2004, 5:45-49.
63. Arkenau H.T., Chong G., Cunningham D., et al. Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 2007, 92:271-272.
64. Spencer A., Reed K., Arthur C. Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. Intern Med J 2007, 37:760-766.
65. Yong W., Zheng W., Zhu J., et al. l-Asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol 2009, 88:647-652.
66. Jaccard A., Petit B., Girault S., et al. l-Asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol 2009, 20:110-116.
67. Jaccard A., Gachard N., Marin B., et al. Efficacy of l-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011, 117:1834-1839.
68. Yamaguchi M., Kwong Y.L., Kim W.S., et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 2011, 29:4410-4416.
69. Tsimberidou A.M., Giles F., Romaguera J., Duvic M., Kurzrock R. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies. Cancer 2004, 100:574-580.
70. Niitsu N., Kohori M., Higashihara M., Bessho M. Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Sci 2007, 98:109-112.
71. Savage K.J. Therapies for peripheral T-cell lymphomas. Hematology (Am Soc Hematol Educ Program) 2011, 2011:515-524.
72. Kim S.J., Kim K., Park Y., et al. Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. Invest New Drugs 2012, 30:368-375.
73. Dearden C.E., Johnson R., Pettengell R., et al. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol 2011, 153:451-485.
74. Reimer P. Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas. Adv Hematol 2010, 2010:320624.
75. Schmitz N., Nickelsen M., Glaß B. Autologous or allogeneic transplantation in B- and T-cell lymphomas. Best Pract Res Clin Haematol 2012, 25:61-73.
76. Hosing C., Champlin R.E. Stem-cell transplantation in T-cell non-Hodgkin's lymphomas. Ann Oncol 2011, 22:1471-1477.
77. d'Amore F., Relander T., Laurtizsen G.F., et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012, 30:3093-3099.
78. Reimer P., Rüdiger T., Geissinger E., et al. Autologous stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009, 27:106-113.
79. Rodríguez J., Conde E., Gutiérrez A., et al. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol 2007, 78:290-296.
80. Jantunen E., Wiklund T., Juvonen E., et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant 2004, 33:405-410.
81. Zamkoff K.W., Matulis M.D., Mehta A.C., Beaty M.W., Hutchison R.E., Gentile T.C. High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy sensitive ALK-negative anaplastic large-cell lymphoma. Bone Marrow Transplant 2004, 33:635-638.
82. Rodríguez J., Caballero M.D., Gutiérrez A., et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 2003, 14:1768-1775.
83. Chen A.I., McMillan A., Negrin R.S., Horning S.J., Laport G.G. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant 2008, 14:741-747.
84. Song K.W., Mollee P., Keating A., Crump M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003, 120:978-985.
85. Kyriakou C., Canals C., Goldstone A., et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008, 26:218-224.
86. Corradini P., Dodero A., Zallio F., et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004, 22:2172-2176.
87. Le Gouill S., Milpied N., Buzyn A., et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol 2008, 26:2264-2271.
88. Dodero A., Spina F., Narni F., et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 2012, 26:520-526.
89. Dhedin N., Giraudier S., Gaulard P., et al. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Sociét Française de Greffe de Moelle. Br J Haematol 1999, 107:154-161.
90. Wulf G.G., Hasenkamp J., Jung W., Chapuy B., Truemper L., Glass B. Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2005, 36:271-273.
91. Shustov A.R., Gooley T.A., Sandmaier B.M., et al. Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. Br J Haematol 2010, 150:170-178.